Clin Transplant Res.  2025 Mar;39(1):1-11. 10.4285/ctr.24.0046.

Current status of pancreatic islet xenotransplantation

• Kim JM
• Park CG

• KMID: 2566575
• DOI: http://doi.org/10.4285/ctr.24.0046

Abstract

Pancreatic islet transplantation represents the optimal treatment for severe hypoglycemia, a serious complication experienced by patients with long-term type 1 diabetes who are undergoing insulin therapy. However, the limited availability of donor organs restricts its widespread use. Porcine pancreatic islets could offer a viable alternative to address this organ shortage. For successful pancreatic islet xenotransplantation using porcine pancreatic islets, efficacy and safety must first be demonstrated in pig-to-nonhuman primate (NHP) preclinical studies, as outlined in the consensus statement of the International Xenotransplantation Association. Our group has achieved long-term survival of wild-type porcine islet grafts in immunosuppressed NHPs by employing two immunosuppressive protocols: one based on CD40-CD40L blockade and another utilizing clinically available immunosuppressants. A clinical trial for pancreatic islet xenotransplantation, following the latter protocol, has received approval from the Korean Ministry of Food and Drug Safety (MFDS). This review aims to highlight the results of clinical trials involving porcine islet xenotransplantation to date, along with the age-specific and other characteristics of the porcine islets used in these trials and the preclinical NHP studies that support them. It offers insights into the perspectives around the first clinical islet xenotransplantation approved by the Korean MFDS, emphasizing improved long-term graft survival.

Keyword

Immunosuppressants; Primate; Pig; Islets of Langerhans; Xenotransplantation

Reference

1. Toren E, Burnette KS, Banerjee RR, Hunter CS, Tse HM. 2021; Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis. Front Immunol. 12:756548. DOI: 10.3389/fimmu.2021.756548. PMID: 34691077. PMCID: PMC8529969.

2. Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, et al. 2008; Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 51:227–32. DOI: 10.1007/s00125-007-0868-9. PMID: 18040664.

3. Rzepczyk S, Dolińska-Kaczmarek K, Uruska A, Żaba C. 2022; The other face of insulin-overdose and its effects. Toxics. 10:123. DOI: 10.3390/toxics10030123. PMID: 35324747. PMCID: PMC8955302.

4. Rother KI, Harlan DM. 2004; Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest. 114:877–83. DOI: 10.1172/JCI23235. PMID: 15467822. PMCID: PMC518676.

5. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. 2000; Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 343:230–8. DOI: 10.1056/NEJM200007273430401. PMID: 10911004.

6. Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, et al. 2016; Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care. 39:1230–40. DOI: 10.2337/dc15-1988. PMID: 27208344. PMCID: PMC5317236.

7. Stabler CL, Russ HA. 2023; Regulatory approval of islet transplantation for treatment of type 1 diabetes: implications and what is on the horizon. Mol Ther. 31:3107–8. DOI: 10.1016/j.ymthe.2023.10.011. PMID: 37865099. PMCID: PMC10638039.

8. Hering BJ, Cooper DK, Cozzi E, Schuurman HJ, Korbutt GS, Denner J, et al. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: executive summary. Xenotransplantation. 16:196–202. DOI: 10.1111/j.1399-3089.2009.00547.x. PMID: 19799759.

9. Schuurman HJ. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 2: source pigs. Xenotransplantation. 16:215–22.

10. Korbutt GS. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 3: pig islet product manufacturing and release testing. Xenotransplantation. 16:223–8. DOI: 10.1111/j.1399-3089.2009.00542.x. PMID: 19799762.

11. Denner J, Schuurman HJ, Patience C. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 5: strategies to prevent transmission of porcine endogenous retroviruses. Xenotransplantation. 16:239–48. DOI: 10.1111/j.1399-3089.2009.00544.x. PMID: 19799764.

12. Cozzi E, Tallacchini M, Flanagan EB, Pierson RN 3rd, Sykes M, Vanderpool HY. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 1: key ethical requirements and progress toward the definition of an international regulatory framework. Xenotransplantation. 16:203–14. DOI: 10.1111/j.1399-3089.2009.00540.x. PMID: 19799760.

13. Groth CG, Korsgren O, Tibell A, Tollemar J, Möller E, Bolinder J, et al. 1994; Transplantation of porcine fetal pancreas to diabetic patients. Lancet. 344:1402–4. DOI: 10.1016/S0140-6736(94)90570-3. PMID: 7968077.

14. Valdes-Gonzalez R, Rodriguez-Ventura AL, White DJ, Bracho-Blanchet E, Castillo A, Ramírez-González B, et al. 2010; Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clin Exp Immunol. 162:537–42. DOI: 10.1111/j.1365-2249.2010.04273.x. PMID: 20964645. PMCID: PMC3026557.

15. Ma X, Li S, Wang J, Xu C, Wang W. 2023; Establishment of a donor pig for xenotransplantation clinical trials based on the principle of Changsha Communiqué. Health Care Sci. 2:129–34. DOI: 10.1002/hcs2.37. PMID: 38938766. PMCID: PMC11080849.

16. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. 2007; Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 14:157–61. DOI: 10.1111/j.1399-3089.2007.00384.x. PMID: 17381690.

17. Skinner SJ, Tan PL, Garkavenko O, Muzina M, Escobar L, Elliott RB. Cell replacement therapy: the rationale for encapsulated porcine islet transplantation, type 1 diabetes complications. InTech;2011. DOI: 10.5772/24824.

18. Matsumoto S, Tan P, Baker J, Durbin K, Tomiya M, Azuma K, et al. 2014; Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 46:1992–5. DOI: 10.1016/j.transproceed.2014.06.008. PMID: 25131091.

19. Matsumoto S, Abalovich A, Wechsler C, Wynyard S, Elliott RB. 2016; Clinical benefit of islet xenotransplantation for the treatment of type 1 diabetes. EBioMedicine. 12:255–62. DOI: 10.1016/j.ebiom.2016.08.034. PMID: 27592597. PMCID: PMC5078586.

20. Park CG, Bottino R, Hawthorne WJ. 2015; Current status of islet xenotransplantation. Int J Surg. 23(Pt B):261–6. DOI: 10.1016/j.ijsu.2015.07.703. PMID: 26253846.

21. Nagaraju S, Bottino R, Wijkstrom M, Trucco M, Cooper DK. 2015; Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation. 22:7–19. DOI: 10.1111/xen.12130. PMID: 25130196.

22. Korbutt GS, Elliott JF, Ao Z, Smith DK, Warnock GL, Rajotte RV. 1996; Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest. 97:2119–29. DOI: 10.1172/JCI118649. PMID: 8621802. PMCID: PMC507287.

23. Matsumoto S, Tomiya M, Sawamoto O. 2016; Current status and future of clinical islet xenotransplantation. J Diabetes. 8:483–93. DOI: 10.1111/1753-0407.12395. PMID: 26987992.

24. Kim JH, Kim HI, Lee KW, Yu JE, Kim SH, Park HS, et al. 2007; Influence of strain and age differences on the yields of porcine islet isolation: extremely high islet yields from SPF CMS miniature pigs. Xenotransplantation. 14:60–6. DOI: 10.1111/j.1399-3089.2006.00364.x. PMID: 17214705.

25. Cooper DK, Casu A. 2009; The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation. 16:229–38. DOI: 10.1111/j.1399-3089.2009.00543.x. PMID: 19799763.

26. Cooper DK, Bottino R, Gianello P, Graham M, Hawthorne WJ, Kirk AD, et al. 2016; First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes: chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation. 23:46–52. DOI: 10.1111/xen.12226. PMID: 26916706.

27. Shin JS, Kim JM, Kim JS, Min BH, Kim YH, Kim HJ, et al. 2015; Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant. 15:2837–50. DOI: 10.1111/ajt.13345. PMID: 26096041.

28. Shin JS, Kim JM, Min BH, Yoon IH, Kim HJ, Kim JS, et al. 2018; Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression. Xenotransplantation. 25:e12356. DOI: 10.1111/xen.12356. PMID: 29057561. PMCID: PMC5809197.

29. Kim JM, Hong SH, Chung H, Shin JS, Min BH, Kim HJ, et al. 2021; Long-term porcine islet graft survival in diabetic non-human primates treated with clinically available immunosuppressants. Xenotransplantation. 28:e12659. DOI: 10.1111/xen.12659. PMID: 33155753.

30. Hering BJ, Wijkstrom M, Graham ML, Hårdstedt M, Aasheim TC, Jie T, et al. 2006; Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 12:301–3. DOI: 10.1038/nm1369. PMID: 16491083.

31. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, et al. 2006; Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med. 12:304–6. DOI: 10.1038/nm1375. PMID: 16501570.

32. van der Windt DJ, Bottino R, Casu A, Campanile N, Smetanka C, He J, et al. 2009; Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant. 9:2716–26. DOI: 10.1111/j.1600-6143.2009.02850.x. PMID: 19845582.

33. Thompson P, Badell IR, Lowe M, Cano J, Song M, Leopardi F, et al. 2011; Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant. 11:2593–602. DOI: 10.1111/j.1600-6143.2011.03720.x. PMID: 21883917. PMCID: PMC3226931.

34. Bottino R, Wijkstrom M, van der Windt DJ, Hara H, Ezzelarab M, Murase N, et al. 2014; Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transplant. 14:2275–87. DOI: 10.1111/ajt.12868. PMID: 25220221. PMCID: PMC4169326.

35. Shin JS, Min BH, Kim JM, Kim JS, Yoon IH, Kim HJ, et al. 2016; Failure of transplantation tolerance induction by autologous regulatory T cells in the pig-to-non-human primate islet xenotransplantation model. Xenotransplantation. 23:300–9. DOI: 10.1111/xen.12246. PMID: 27387829.

36. Hawthorne WJ, Salvaris EJ, Chew YV, Burns H, Hawkes J, Barlow H, et al. 2022; Xenotransplantation of genetically modified neonatal pig islets cures diabetes in baboons. Front Immunol. 13:898948. DOI: 10.3389/fimmu.2022.898948. PMID: 35784286. PMCID: PMC9243461.

37. Thompson P, Cardona K, Russell M, Badell IR, Shaffer V, Korbutt G, et al. 2011; CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 11:947–57. DOI: 10.1111/j.1600-6143.2011.03509.x. PMID: 21521467. PMCID: PMC4845096.

38. Thompson P, Badell IR, Lowe M, Turner A, Cano J, Avila J, et al. 2012; Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant. 12:1765–75. DOI: 10.1111/j.1600-6143.2012.04031.x. PMID: 22458586. PMCID: PMC3387302.

39. Hecht G, Eventov-Friedman S, Rosen C, Shezen E, Tchorsh D, Aronovich A, et al. 2009; Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci U S A. 106:8659–64. DOI: 10.1073/pnas.0812253106. PMID: 19433788. PMCID: PMC2688963.

40. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. 1996; Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest. 98:1417–22. DOI: 10.1172/JCI118929. PMID: 8823307. PMCID: PMC507568.

41. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, et al. 2005; Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc. 37:3505–8. DOI: 10.1016/j.transproceed.2005.09.038. PMID: 16298643.

42. Dufrane D, Goebbels RM, Gianello P. 2010; Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 90:1054–62. DOI: 10.1097/TP.0b013e3181f6e267. PMID: 20975626.

43. Vériter S, Gianello P, Igarashi Y, Beaurin G, Ghyselinck A, Aouassar N, et al. 2014; Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. 23:1349–64. DOI: 10.3727/096368913X663550. PMID: 23461890.

44. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, et al. 2002; Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science. 295:1089–92. DOI: 10.1126/science.1068228. PMID: 11778012.

45. Hawthorne WJ, Lew AM, Thomas HE. 2016; Genetic strategies to bring islet xenotransplantation to the clinic. Curr Opin Organ Transplant. 21:476–83. DOI: 10.1097/MOT.0000000000000353. PMID: 27517501.

46. Hamawy MM. 2003; Targeting proximal T cell receptor signaling in transplantation. Transplantation. 75:1921–7. DOI: 10.1097/01.TP.0000070168.42915.47. PMID: 12829888.

47. Pallet N, Fernández-Ramos AA, Loriot MA. 2018; Impact of immunosuppressive drugs on the metabolism of T cells. Int Rev Cell Mol Biol. 341:169–200. DOI: 10.1016/bs.ircmb.2018.05.009. PMID: 30262032.

48. Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Pract Res Clin Gastroenterol. 2021; 54-55:101757. DOI: 10.1016/j.bpg.2021.101757. PMID: 34874841.

49. Laman JD, Claassen E, Noelle RJ. 2017; Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 37:371–420. DOI: 10.1615/CritRevImmunol.v37.i2-6.100. PMID: 29773027.

50. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. 2000; Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 6:114. DOI: 10.1038/72162.

51. Laman JD, Molloy M, Noelle RJ. 2024; Switching off autoimmunity. Science. 385:827–9. DOI: 10.1126/science.ade6949. PMID: 39172850.

52. GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espié P, Dupuy C, et al. 2024; Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study. J Clin Neurosci. 119:76–84. DOI: 10.1016/j.jocn.2023.11.013. PMID: 37988976.

53. Nilsson B, Ekdahl KN, Korsgren O. 2011; Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant. 16:620–6. DOI: 10.1097/MOT.0b013e32834c2393. PMID: 21971510.

54. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. 2014; Inflammatory response in islet transplantation. Int J Endocrinol. 2014:451035. DOI: 10.1155/2014/451035. PMID: 24883060. PMCID: PMC4021753.

55. Lim H, Lee SH, Lee HT, Lee JU, Son JY, Shin W, et al. 2018; Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 19:768. DOI: 10.3390/ijms19030768. PMID: 29518978. PMCID: PMC5877629.

56. Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. 2017; Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 36:191–7. DOI: 10.1007/s10067-016-3506-4. PMID: 27981463.

57. Speake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, et al. 2022; IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function. JCI Insight. 7:e159436. DOI: 10.1172/jci.insight.159436. PMID: 36282595. PMCID: PMC9746808.

58. Gille I, Claas FH, Haasnoot GW, Heemskerk MH, Heidt S. 2022; Chimeric antigen receptor (CAR) regulatory T-cells in solid organ transplantation. Front Immunol. 13:874157. DOI: 10.3389/fimmu.2022.874157. PMID: 35720402. PMCID: PMC9204347.

59. Zimmermann K, Noyan F, Hust M, Schwinzer R, Hundrieser J, Hardtke-Wolenski M, et al. 2018; Operational tolerance in xenotransplantation by use of regulatory T cells with a SLA-specific chimeric antigen receptor. Transplantation. 102:S742. DOI: 10.1097/01.tp.0000543734.57229.97.